Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation

Long Covid” and its many symptoms maybe related with mononucleosis virus [Epostein-Barr]
I have a very positive experience with the treatment of Mono with homeopathic Epstein-Barr [from a London Pharmacy and because that I suggested trying to make a homeopathic dilution[“isopathy”]from corona[secretion] under strict supervision[even if anyone could do that but at great risk] but not a single soul reacted on this suggestion of course…

If it had been tried and worked there would not have been any Covid or variants in the world and any country could have prepared this for themselves for a few thousand dollars at most!! Never too late, certainly not now when we have shown to have no solutions!!
Even not from the homeopathic world i got any reaction possibly because out of fear for legal problems [Maybe some in India have used this method on a private[secret] base?
With this new article I would definitely suggest trying the Epstein Barr nosode/isopathy for “long Covid”.
I can be ordered from Ainsworth’s in England.[see above]

Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation

Jeffrey E. Gold,1,*Ramazan A. Okyay,2Warren E. Licht,3 and David J. Hurley4Lisa Gralinski, Academic EditorAuthor informationArticle notesCopyright and License informationDisclaimerThis article has been cited by other articles in PMC.

Associated Data

Data Availability StatementGo to:

Abstract

Coronavirus disease 2019 (COVID-19) patients sometimes experience long-term symptoms following resolution of acute disease, including fatigue, brain fog, and rashes. Collectively these have become known as long COVID. Our aim was to first determine long COVID prevalence in 185 randomly surveyed COVID-19 patients and, subsequently, to determine if there was an association between occurrence of long COVID symptoms and reactivation of Epstein–Barr virus (EBV) in 68 COVID-19 patients recruited from those surveyed. We found the prevalence of long COVID symptoms to be 30.3% (56/185), which included 4 initially asymptomatic COVID-19 patients who later developed long COVID symptoms. Next, we found that 66.7% (20/30) of long COVID subjects versus 10% (2/20) of control subjects in our primary study group were positive for EBV reactivation based on positive titers for EBV early antigen-diffuse (EA-D) IgG or EBV viral capsid antigen (VCA) IgM. The difference was significant (p < 0.001, Fisher’s exact test). A similar ratio was observed in a secondary group of 18 subjects 21–90 days after testing positive for COVID-19, indicating reactivation may occur soon after or concurrently with COVID-19 infection. These findings suggest that many long COVID symptoms may not be a direct result of the SARS-CoV-2 virus but may be the result of COVID-19 inflammation-induced EBV reactivation.